论文部分内容阅读
本文对慢性乙肝患者15例用无环鸟苷与干扰素进行抗病毒治疗,每例治前肝穿活检,PAP法检测肝细胞内HBsAg、HBcAg,用显微分光光度计进行抗原定量测定。治后根据血清乙肝病毒复制指标分有效组与无效组,结果两组之间肝细胞内HBsAg、HBcAg在治毕及治后半年含量变化无差异,一年后HBsAgLOD值,HBcAg OD值P<0.01呈负相关,提示肝细胞内乙肝病毒抗原含量变化与抗病毒治疗疗效无相关性,这种无差异和负相关提示肝细胞内有乙肝病毒复制外,肝外组织也可能有乙肝病毒复制,二者联合治疗除了直接抑制病毒蛋白合成和HBV-DNAP活性外,推测其疗效与机体免疫反应也密切相关。
In this paper, 15 cases of chronic hepatitis B patients with acyclovir and interferon for antiviral therapy, liver biopsy before each treatment, PAP detection of intrahepatic HBsAg, HBcAg, using a micro-spectrophotometer antigen quantitative determination. After treatment, according to the index of serum hepatitis B virus replication, the effective and invalid groups were divided into two groups. Results There was no difference in the content of HBsAg and HBcAg between the two groups after treatment and half a year after treatment. One year later HBsAgLOD and HBcAg OD values were less than 0.01 Negative correlation, suggesting that changes in the content of hepatitis B virus antigen in hepatocytes had no correlation with the efficacy of antiviral therapy. This no difference and negative correlation suggested that there was hepatitis B virus replication in hepatocytes. Extrahepatic tissues may also have hepatitis B virus replication. Combination therapy in addition to direct inhibition of viral protein synthesis and HBV-DNAP activity, suggesting that its efficacy and the immune response are also closely related.